WuXi Biologics announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Located on a 13.5-hectare site in Tuas Biomedical Park, the Hub will be the first of its kind in Singapore, built on WuXi Biologics' proprietary technology platforms and industry-leading capabilities to offer dual sourcing solutions for biopharmaceutical companies worldwide. The Hub will add 120,000 liters of manufacturing capacity to the Company's global network, reinforcing Singapore's position as a leading biopharmaceutical hub.

On this site, WuXi Biologics' subsidiary WuXi XDC achieved mechanical completion of its Singapore ADC production site in 2025. Spanning approximately 30,000 square meters, the modular DP facility will feature advanced manufacturing lines, centralized Quality Control (QC) labs for full release and stability testing, and Manufacturing Science and Technology (MSAT) labs, significantly expanding the Company's end-to-end DP capabilities. With three pre-filled syringe (PFS) lines and two vial lines for liquid and lyophilized products, it will deliver integrated DP manufacturing for multiple dosage forms across clinical and commercial stages.

The facility will also incorporate green technologies, including solar panels and an advanced system for energy monitoring and analysis. Operations are expected to commence in 2027. Construction across the Singapore CRDMO hub continues to advance, with the drug substance facility currently in the design phase.

The Hub marks a significant step in WuXi Biologics' global extension and its long-term commitment as the partner of choice for global biopharmaceutical companies.